Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Marques, Cynthia
DREAM, NCT05787795: Identifying and Characterizing Preclinical MS	Recruiting	N/A	1000	US	biological samples	Yale University, Roche-Genentech	Multiple Sclerosis	06/32	06/33
Longbrake, Erin
CELLO, NCT04877457: Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.	Terminated	4	3	US	Ocrelizumab, Placebo	Yale University, Genentech, Inc.	Radiologically Isolated Syndrome, Multiple Sclerosis	06/23	06/23
NCT05285891: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Recruiting	4	123	US	Ocrelizumab, Ocrevus, Placebo for Ocrelizumab	National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence (ACE), Rho Federal Systems Division, Inc., Genentech, Inc.	Multiple Sclerosis	08/28	08/28
DREAM, NCT05787795: Identifying and Characterizing Preclinical MS	Recruiting	N/A	1000	US	biological samples	Yale University, Roche-Genentech	Multiple Sclerosis	06/32	06/33